Mrs Chris Houska, MS in Cavalier, ND - Speech-Language Pathologist

Mrs Chris Houska, MS is a Speech-language Pathologist based in Cavalier, North Dakota. Mrs Chris Houska is licensed to practice in North Dakota (license number 365) and her current practice location is 106b Division Ave. N., Cavalier, North Dakota. She can be reached at her office (for appointments etc.) via phone at (701) 265-8080.

NPI number for Mrs Chris Houska is 1508982547 and her current mailing address is 1423 Manvel Ave, Grafton, North Dakota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1508982547.

Contact Information

	Mrs Chris Houska, MS
	106b Division Ave. N., Cavalier, ND 58220
	(701) 265-8080
	Not Available

Healthcare Provider's Profile

Full Name	Mrs Chris Houska
Gender	Female
Speciality	Speech-language Pathologist
Location	106b Division Ave. N., Cavalier, North Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1508982547
Provider Enumeration Date: 03/21/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mrs Chris Houska such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1508982547	NPI	-	NPPES
59449	Medicaid	ND
365	Other	ND	STATE LICENSE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	365 (North Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Chris Houska is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Chris Houska, MS 1423 Manvel Ave, Grafton, ND 58237-1869 Ph: (701) 352-2186	Mrs Chris Houska, MS 106b Division Ave. N., Cavalier, ND 58220 Ph: (701) 265-8080

News Archive

K2M granted FDA clearance for CHESAPEAKE Anterior-Lumbar Stabilization System

K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

High serum insulin levels linked with increased risk of prostate cancer

Demetrius Albanes, M.D., of the Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., and colleagues investigated the relationship of the level of serum insulin and glucose, as well as surrogate indices of insulin resistance, to the development of prostate cancer.

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

Speech-Language Pathologist in Cavalier, ND

Mrs. Brenda Sue Brumbaugh, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 Main St. East, Cavalier, ND 58220 Phone: 701-265-8417
Mrs. Tami Christianson-larson, M.S., CCC, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 106b Division Ave. N., Cavalier, ND 58220 Phone: 701-265-8080

Mrs Chris Houska, MS - Speech-Language Pathologist in Cavalier, ND